Results 91 to 100 of about 1,936 (153)

Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar

open access: yes, 2019
Objectives: To investigate the in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against clinical isolates of MDR Pseudomonas aeruginosa from Qatar, as well as the mechanisms of resistance. Methods: MDR P. aeruginosa isolated between
Jass, Jana   +27 more
core   +1 more source

Trends in Pseudomonas aeruginosa In Vitro Susceptibility to Ceftolozane/Tazobactam in Latin America: SMART Surveillance Program, 2016–2024

open access: yesAntibiotics
Objectives: To describe annual trends in the susceptibility of clinical isolates of Pseudomonas aeruginosa from Latin America to ceftolozane/tazobactam.
Mark G. Wise   +6 more
doaj   +1 more source

Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition [PDF]

open access: yes
Ceftolozane-tazobactam (CT) is used for the treatment of complicated infections and for multidrug-resistant strains of Pseudomonas aeruginosa and extended-spectrum beta-lactamase-producing enterobacteria.
Noe Garin   +16 more
core   +1 more source

Targeting Pseudomonas aeruginosa resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion [PDF]

open access: yes
Ceftolozane/tazobactam is a key antibiotic for Pseudomonas aeruginosa infections. Our objective was to determine whether continuous infusion (CI) of ceftolozane/tazobactam can achieve aggressive pharmacokinetic/pharmacodynamic (PK/PD) targets that ...
Gatti, Milo   +7 more
core   +1 more source

In vitro susceptibility profile of BLEES-positive Enterobacteriaceae isolated from clinical specimens to ceftolozane/tazobactam [PDF]

open access: yes, 2019
Las Enterobacterias son un grupo grande y heterogéneo de bacterias gramnegativas, las cuales se caracterizan por su capacidad de producir infecciones en pacientes inmunocompetentes e inmunosuprimidos tanto de la comunidad como en el ambiente ...
Valderrama Rodríguez, Cristian Camilo
core   +1 more source

Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia

open access: yes, 2020
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Patients admitted to hospitals are at risk of developing nosocomial infections. These types of infections typically occur in immune compromised patients.
Martin-Loeches I, Bisanti A, Diaz E, Rodriguez A
core  

Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?

open access: yesAntimicrobial Agents and Chemotherapy
Ceftolozane/tazobactam is widely used against extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, yet FDA-approved dosing relies on intermittent infusion and a fixed 2:1 ratio that assumes adequate β-lactamase inhibition. Tazobactam’s faster
Manjunath P. Pai   +7 more
doaj   +1 more source

Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency

open access: yes, 2018
We report the successful use of ceftolozane/tazobactam (C/T) to treat a pulmonary exacerbation in a 35 year old female, post lung transplant, with cystic fibrosis (CF), malnutrition, chronic kidney disease, and multi-drug resistant Pseudomonas aeruginosa
Stokem, Katie   +9 more
core   +1 more source

Prevalence of resistance to ceftolozane/tazobactam among Escherichia coli clinical isolates susceptible or resistant to alternative agents.

open access: yes, 2018
Prevalence of resistance to ceftolozane/tazobactam among Escherichia coli clinical isolates susceptible or resistant to alternative agents.
Brian D. Johnston (580892)   +2 more
core   +1 more source

Use of Ceftolozane-Tazobactam in Patient with Severe Medium Chronic Purulent Otitis by XDR Pseudomonas aeruginosa

open access: yes, 2019
We present a case of a male Italian patient of 66 years with a history of kidney transplantation in treatment with cyclosporine and methylprednisolone. He visited an ENT clinic and was diagnosed as chronic left purulent otitis media.
F. Lavagna   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy